The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Clinical trials on drug repositioning for COVID-19 treatment
Open accessAbstract
The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus Betacoronavirus, that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants’ clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Interferon-stimulated genes: A complex web of host defenses
Schneider, W. M., Chevillotte, M. D., & Rice, C. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120231 · Cited by 3,067
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Li, G., & De Clercq, E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00016-0 · Cited by 1,729
Zhong, N., Zheng, B., Li, Y., Poon, L., Xie, Z., Chan, K., Li, P., Tan, S., Chang, Q., Xie, J., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14630-2 · Cited by 1,579
Lee, N., Allen Chan, K. C., Hui, D. S., Ng, E. K. O., Wu, A., Chiu, R. W. K., Wong, V. W. S., Chan, P. K. S., Wong, K. T., Wong, E., et al. (2004) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.07.006 · Cited by 636
Arbidol as a broad-spectrum antiviral: An update
Blaising, J., Polyak, S. J., & Pécheur, E.-I. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.04.006 · Cited by 485
Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
Wang, Y., Fei, D., Vanderlaan, M., & Song, A. (2004) · Angiogenesis · doi:10.1007/s10456-004-8272-2 · Cited by 430
Rolain, J.-M., Colson, P., & Raoult, D. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.05.015 · Cited by 401
2019 Novel Coronavirus—Important Information for Clinicians
del Rio, C., & Malani, P. N. (2020) · JAMA · doi:10.1001/jama.2020.1490 · Cited by 377
Drug Repurposing for Viral Infectious Diseases: How Far Are We?
Mercorelli, B., Palù, G., & Loregian, A. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.04.004 · Cited by 264
And the MIRACLE trial group, Arabi, Y. M., Alothman, A., Balkhy, H. H., Al-Dawood, A., AlJohani, S., Al Harbi, S., Kojan, S., Al Jeraisy, M., Deeb, A. M., et al. (2018) · Trials · doi:10.1186/s13063-017-2427-0 · Cited by 253
Mathias, A. A., German, P., Murray, B. P., Wei, L., Jain, A., West, S., Warren, D., Hui, J., & Kearney, B. P. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.228 · Cited by 205
The Emerging Role of Vitamin C as a Treatment for Sepsis
Kashiouris, M. G., L’Heureux, M., Cable, C. A., Fisher, B. J., Leichtle, S. W., & Fowler, A. A. (2020) · Nutrients · doi:10.3390/nu12020292 · Cited by 177
Cherin, P., Marié, I., Michallet, M., Pelus, E., Dantal, J., Crave, J., Delain, J.-C., & Viallard, J. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.09.002 · Cited by 139
More than 80 clinical trials launch to test coronavirus treatments
Maxmen, A. (2020) · Nature · doi:10.1038/d41586-020-00444-3 · Cited by 133
Nassar, M. S., Bakhrebah, M. A., Meo, S. A., Alsuabeyl, M. S., & Zaher, W. A. (2018) · PubMed · doi:10.26355/eurrev_201808_15635 · Cited by 129
Application of Chinese Medicine in Acute and Critical Medical Conditions
Luo, Y., Wang, C., Hesse-Fong, J., Lin, J., & Yuan, C. (2019) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x19500629 · Cited by 128
Renovation as innovation: is repurposing the future of drug discovery research?
Neuberger, A., Oraiopoulos, N., & Drakeman, D. L. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.06.012 · Cited by 79
Repurposing host-based therapeutics to control coronavirus and influenza virus
Li, C.-C., Wang, X.-J., & Wang, H. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.01.018 · Cited by 72
Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Al‐Tawfiq, J. A., & Memish, Z. A. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1271712 · Cited by 53
Oseltamivir Treatment of Influenza in Children
Uyeki, T. M. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1150 · Cited by 49
Okubo, K., Isono, M., Asano, T., & Sato, A. (2019) · Anticancer Research · doi:10.21873/anticanres.13793 · Cited by 37
Broadly neutralizing antibodies for therapy of viral infections
Varadarajan, R., Srinivasan, S., Maity, S., & Ghosh, M. (2016) · Antibody Technology Journal · doi:10.2147/anti.s92190 · Cited by 11
Cited by
Sharma, A., Ahmad Farouk, I., & Lal, S. K. (2021) · Viruses · doi:10.3390/v13020202 · Cited by 703
An Update on Current Therapeutic Drugs Treating COVID-19
Wu, R., Wang, L., Kuo, H.-C. D., Shannar, A., Peter, R., Chou, P. J., Li, S., Hudlikar, R., Liu, X., Liu, Z., et al. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00216-7 · Cited by 599
Drug repurposing approach to fight COVID-19
Singh, T. U., Parida, S., Lingaraju, M. C., Kesavan, M., Kumar, D., & Singh, R. K. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00155-6 · Cited by 480
Ortiz-Prado, E., Simbaña-Rivera, K., Gómez- Barreno, L., Rubio-Neira, M., Guaman, L. P., Kyriakidis, N. C., Muslin, C., Jaramillo, A. M. G., Barba-Ostria, C., Cevallos-Robalino, D., et al. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115094 · Cited by 458
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375
“SARS-CoV-2 does not express neuraminidase therefore combination therapy of oseltamivir together with protease inhibitors has shown efficacy [140,141].”
Metadata
- Authors
- Rosa, S. G. V., & Santos, W. C.
- Venue
- Revista Panamericana de Salud Pública
- Publisher
- Pan American Health Organization
- Published
- 2020-03-30
- Volume
- 44
- Pages
- 1
- ISSN
- 1020-4989 (ISSN-L)
- 1680-5348
- OpenAlex
- W3013953493
- Cited by
- 420
- References
- 30
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.